ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.742,22
-0,08%
S&P 500
5.221,42
-0,02%
Dow Jones
39.431,51
-0,21%
Euro vs US Dollar
1,07897
0,18%
Bitcoin
63.089,56
2,67%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) News

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CTMX
DatumZeitQuelleÜberschriftSymbolFirma
13/05/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h10GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h10GlobeNewswire Inc.CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)NASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
07/05/202422h15GlobeNewswire Inc.CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:CTMXCytomX Therapeutics Inc
01/05/202414h00GlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
08/04/202414h00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
03/04/202414h00GlobeNewswire Inc.CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
21/03/202413h00GlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h10GlobeNewswire Inc.CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTMXCytomX Therapeutics Inc
11/03/202411h39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:CTMXCytomX Therapeutics Inc
04/03/202414h00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024NASDAQ:CTMXCytomX Therapeutics Inc
27/02/202414h00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
24/01/202414h00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
20/01/202402h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
20/01/202402h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
20/01/202402h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
20/01/202402h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
20/01/202402h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
12/01/202414h00GlobeNewswire Inc.CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.CytomX Therapeutics Outlines 2024 Company Priorities and MilestonesNASDAQ:CTMXCytomX Therapeutics Inc
22/12/202322h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
22/12/202322h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
22/12/202322h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

Kürzlich von Ihnen besucht

NASDAQ
CFSB
CFSB Bancorp
AQSE
TES0.GB
Test Stock 0
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten